The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...

All of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the ...

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

Genentech, a member of the Roche Group (SIX ... Including a Potential Sale Vista Outdoor Inc. ("Vista Outdoor", the "Company") today issued the following statement from the Company's Chairman of the ...

SWANTON — Three alumni from graduating classes in the 1990s and early 2000s were inducted into the Missisquoi Valley Union ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

Mr. Mullins added, “I am thrilled to join Tempest at such an exciting time as the team prepares to advance amezalpat into a pivotal study. Amezalpat has demonstrated very strong results in the ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

The action-packed BlackStars Experience, which includes a full day summit and awards will take place in New York City on ...